Small human study links frailty to a cell-free DNA methylation pattern

A peer-reviewed study published September 4 in *Cell Death & Disease* has linked frailty in older adults to altered DNA-damage signals and a distinctive methylation pattern in circulating cell-free DNA. The findings could inform biomarker research, but the small, cross-sectional study did not test whether the molecular signals predict future decline or improve frailty diagnosis.

Circulating cell-free DNA, or cfDNA, consists of DNA fragments released into the bloodstream, often as cells die or sustain injury. It is already studied extensively in cancer and prenatal testing. Earlier research also associated higher concentrations of certain cfDNA species with inflammation and frailty among very old adults, providing a basis for the new investigation.

Three groups, several laboratory endpoints

Researchers recruited 112 people in Pavia, Italy, between December 2018 and March 2021. Participants were classified as young and non-frail, older and non-frail, or older and frail. Frailty was defined using the SHARE-FI instrument, which assesses exhaustion, weight loss, grip strength, slowness and low physical activity. People with dementia, inflammatory or autoimmune disease, chronic immunosuppressive treatment, or recent cancer therapy were excluded.

Available samples differed across experiments. The fibroblast analysis included 18 people per group. The plasma cfDNA analysis included 24 young controls, 15 older controls and 22 frail older adults. Mean ages were approximately 79 years in the frail group and 74 years among older controls in the cfDNA analysis.

Investigators first examined skin fibroblasts for two markers associated with the cellular response to DNA double-strand breaks: phosphorylated H2AX and 53BP1. Under baseline conditions, fibroblasts from frail participants showed more cells with moderate numbers of these damage-associated foci than cells from age-matched controls. After the cells received ionizing radiation, however, the acute damage response was not significantly impaired in the frail group relative to older controls.

That distinction matters. The experiment points to a higher background burden of DNA-damage signaling, not a demonstrated inability to respond to an acute insult. The measurements were also made in cultured skin cells rather than directly across organs in the body.

A methylation signal from a very small subset

Plasma cfDNA concentrations in frail participants were more variable and skewed toward higher values. The frail group also had higher tumor necrosis factor-alpha, an inflammatory marker. TNF-alpha correlated with SHARE-FI scores, but cfDNA concentration did not correlate directly with TNF-alpha, age, cognition or body mass index.

For methylation sequencing, the researchers selected the five participants with the highest cfDNA concentrations from each group—15 people in total. They identified 1,470 differentially methylated regions separating frail participants from older non-frail controls; 1,448 were hypomethylated and 22 were hypermethylated. Only 11 regions differed between the selected young and older non-frail groups.

Computational enrichment analyses connected parts of the frailty-associated pattern with genes expressed in the stomach and lung. A further pathway analysis suggested the small intestine as one possible tissue source. These are bioinformatic inferences, not direct evidence that intestinal tissue released the DNA or that gut dysfunction caused frailty.

What the study does—and does not—establish

The work adds molecular detail to an association reported in a 2013 study of 144 nonagenarians and 30 young controls, where higher total and unmethylated cfDNA tracked with inflammation and frailty. The new study extends that line of research by examining cultured fibroblasts and cfDNA methylation, but it does not independently validate a clinical classifier.

Important limitations include the modest group sizes, use of only five selected samples per group for methylation analysis, and lack of an external validation cohort. The study measured participants at one point rather than following them to determine whether the signals forecast worsening frailty, disability, hospitalization or mortality. Researchers also assessed the radiation response at only one post-exposure time point.

The practical conclusion is therefore limited: cfDNA methylation deserves further prospective study as a possible molecular marker of frailty. Larger, independently recruited cohorts would need to establish accuracy, reproducibility and added value beyond existing clinical assessments before the pattern could support patient care.